SUPN Supernus, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1625297 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.3%
TTM net income YoY251.6%
TTM EPS YoY253.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin85.0%
Operating margin40.6%
Net margin32.8%
FCF margin2.3%
EBITDA margin41.1%
Returns
ROE—
ROA32.8%
ROIC (approx.)—
Asset turnover1.00x
Leverage & solvency
Liabilities / assets104.5%
Debt / equity—
Current ratio0.61x
Interest coverage32.82x
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio25.8%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.24B | $1.19B | $1.09B | $901.00M | $791.00M |
| Cost of revenue | $246.00M | $231.00M | $174.00M | $151.00M | $127.00M |
| Gross profit | $994.00M | $957.00M | $919.00M | $749.00M | $664.00M |
| R&D expense | $97.00M | $107.00M | $116.00M | $74.00M | $52.00M |
| SG&A expense | $634.00M | $612.00M | $565.00M | $469.00M | $431.00M |
| Operating income | $262.00M | $38.00M | -$152.00M | -$81.00M | $213.00M |
| Interest expense | $45.00M | $41.00M | $35.00M | $27.00M | $27.00M |
| Pretax income | $239.00M | $20.00M | -$145.00M | -$89.00M | $190.00M |
| Income tax | $29.00M | $13.00M | -$19.00M | -$44.00M | -$15.00M |
| Net income | $210.00M | $7.00M | -$126.00M | -$44.00M | $205.00M |
| EBITDA | $272.00M | $54.00M | -$137.00M | -$65.00M | $228.00M |
| EPS (basic) | 1.68 | 0.05 | -0.92 | -0.32 | — |
| EPS (diluted) | 1.64 | 0.05 | -0.92 | -0.32 | — |
| Weighted avg. shares (diluted) | 128.00M | 133.00M | 137.00M | 139.00M | 151.94M |
| Balance sheet | |||||
| Cash & equivalents | $195.00M | $319.00M | $316.00M | $774.00M | $1.10B |
| Short-term investments | $0 | $1.00M | $94.00M | — | — |
| Receivables | $253.00M | $254.00M | $254.00M | $220.00M | $202.00M |
| Inventory | $153.00M | $167.00M | $126.00M | $114.00M | $95.00M |
| Current assets | $652.00M | $827.00M | $1.26B | $1.26B | $1.44B |
| PP&E, net | $144.00M | $100.00M | $84.00M | $54.00M | $58.00M |
| Goodwill | $2.00M | $2.00M | $5.00M | — | — |
| Total assets | $1.20B | $1.32B | $1.76B | $1.77B | $1.83B |
| Current liabilities | $914.00M | $924.00M | $1.28B | $1.02B | $804.00M |
| Short-term debt | $29.00M | $18.00M | $3.00M | $3.00M | $3.00M |
| Long-term debt | $290.00M | $315.00M | $237.00M | $237.00M | $239.00M |
| Total debt | $319.00M | $333.00M | $240.00M | $240.00M | $242.00M |
| Total liabilities | $1.30B | $1.65B | $1.94B | $1.72B | $1.63B |
| Shareholders' equity | -$98.00M | -$337.00M | -$184.00M | -$15.00M | $121.00M |
| Net debt | $124.00M | $14.00M | -$76.00M | -$534.00M | -$860.00M |
| Cash flow statement | |||||
| Operating cash flow | -$27.00M | $36.00M | -$300.00M | -$4.00M | $353.00M |
| Capital expenditure | $66.00M | $29.00M | $8.00M | $5.00M | $4.00M |
| Free cash flow | -$93.00M | $7.00M | -$308.00M | -$9.00M | $349.00M |
| Investing cash flow | -$66.00M | $69.00M | -$95.00M | -$222.00M | -$14.00M |
| Financing cash flow | -$30.00M | -$102.00M | -$64.00M | -$101.00M | -$94.00M |
| Depreciation & amortization | $10.00M | $16.00M | $15.00M | $16.00M | $15.00M |
| Stock-based compensation | $26.00M | $24.00M | $21.00M | $16.00M | $11.00M |
| Share buybacks | $11.00M | $173.00M | $33.00M | $90.00M | $101.00M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.